Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
This invention is directed to myocardial imaging of human patients having a history of asthma or bronchospasm. In particular, the present invention uses binodenoson as a pharmacological stressor in conjunction with any one of several noninvasive and invasive diagnostic procedures available. For example, intravenous administration may be used in conjunction with a radiopharmaceutical agent and myocardial perfusion imaging to assess the severity of myocardial ischemia.
1 . A method of diagnosing myocardial dysfunction in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation; and
(b) detecting myocardial dysfunction in the human patient.
2 . The method of claim 1 , wherein the binodenoson is administered as a bolus dose to said human patient.
3 . The method of claim 2 , wherein about 0.5 to about 2.5 μg/kg of the binodenoson is administered to said human patient.
4 . The method of claim 1 , wherein binodenoson is administered by infusion to said human patient.
5 . The method of claim 4 wherein about 0.3 to about 2.0 μg/kg/min of the binodenoson is administered to said human patient.
6 . The method of claim 1 , wherein the myocardial dysfunction is coronary artery disease, ventricular dysfunction, differences in blood flow through disease free coronary vessels and stenotic vessels, or combinations thereof.
7 . The method of claim 1 , wherein step (b) comprises a noninvasive myocardial imaging procedure.
8 . The method of claim 7 , wherein the noninvasive imaging procedure comprises administration of an imaging agent.
9 . A method of diagnosing coronary artery disease in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation;
(b) administering an imaging agent to the human patient; and
(c) performing myocardial perfusion imaging on the human patient to detect coronary artery disease.
10 . A method of diagnosing ventricular dysfunction caused by coronary artery disease, in a human patient having a history of asthma or bronchospasm, comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation; and
(b) performing a ventricular function imaging technique on the human patient to detect ventricular dysfunction.
11 . A method of diagnosing perfusion abnormalities in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation; and
(b) detecting perfusion abnormalities in the human patient.
12 . The method of claim 11 , wherein step (b) comprises measuring coronary blood flow velocity on the human patient to assess the vasodilatory capacity of diseased coronary vessels as compared with disease free coronary vessels.
13 . The method of claim 11 , wherein step (b) comprises assessing the vasodilatory capacity (reserve capacity) of diseased coronary vessels as compared with disease-free coronary vessels.
14 . A method of diagnosing the presence and assessing the severity of coronary artery disease in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation;
(b) administering a radiopharmaceutical agent to the human patient; and
(c) performing scintigraphy on the human patient to detect the coronary artery disease.
15 . A method of diagnosing the presence and assessing the severity of ventricular dysfunction in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering by an intravenous route to the human patient about 0.1 to about 10 μg/kg of binodenoson to provide coronary artery dilation; and
(b) performing echocardiography on the human patient to detect ventricular dysfunction.
16 . A method of diagnosing myocardial dysfunction in a human patient having a history of asthma or bronchospasm comprising the steps of:
(a) administering about 1.5 μg/kg of binodenoson by bolus dosing intravenously to provide coronary artery dilation; and
(b) detecting myocardial dysfunction in the human patient.
17 . A kit comprising, a first container containing a unit dosage of binodenoson, and a second container containing an imaging agent, an adenosine antagonist or a β-2 agonist.
18 . The kit of claim 17 , wherein the second container contains the imaging agent.
19 . The kit of claim 17 , wherein the second container contains an adenosine antagonist.
20 . The kit of claim 17 , wherein the second container contains a β-2 agonist.